Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy-Reference-Cited by-同舟云学术

Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy

Published:2021-10-22 Issue: Volume: Page:
ISSN:1557-1890
Container-title:Journal of Neuroimmune Pharmacology
language:en
Short-container-title:J Neuroimmune Pharmacol

Author:

Sebbag Eden^ORCID,Psimaras Dimitri,Baloglu Seyyid,Bourgmayer Agathe,Moinard-Butot Fabien,Barthélémy Philippe,Tranchant Christine,Honnorat Jerome,Bender Laura

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Immunology,Immunology and Allergy,Neuroscience (miscellaneous)

Link

https://link.springer.com/content/pdf/10.1007/s11481-021-10026-3.pdf

Reference12 articles.

1. Do LD, Gupton SL, Tanji K, Bastien J, Brugière S, Couté Y et al (2019) TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration. Cerebellum 18(2):245–254. Available from: https://doi.org/10.1007/s12311-018-0987-5

2. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M et al (2018) Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209–003 Study. JCO 36(17):1675–1684. Available from: https://doi.org/10.1200/JCO.2017.77.0412

3. Iams WT, Shiuan E, Meador CB, Roth M, Bordeaux J, Vaupel C et al (2019) Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes. J Thorac Oncol 14(11):1970–1981. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1556086419304630

4. Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134. Available from: https://doi.org/10.1186/s40425-019-0617-x

5. Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN et al (2019) Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis 78(1):150–152

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver Cancer with Overlapping Myasthenia Gravis, Myocarditis, Seronegative Autoimmune Autonomic Ganglionopathy, and Myositis Symptoms Induced by Atezolizumab;Internal Medicine;2024-08-01

2. アテゾリズマブ・ベバシズマブ併用療法後自己免疫性脳炎を発症し，改善後に2次治療に移行した肝細胞癌の1例;Kanzo;2023-11-01

3. Detection of High‐Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins;Annals of Neurology;2023-09-19

4. Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review;Journal of Oncology Pharmacy Practice;2023-06-15

5. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management;Expert Review of Clinical Pharmacology;2023-05-04